



- 30 Colin S Brown, FRCPATH, UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division & NIHR Health Protection  
31 Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, NW9 5EQ, England,  
32 <https://orcid.org/0000-0003-4776-3403>  
33 Meera Chand, FRCPATH, UKHSA Genomics and Public Health Analysis, London, NW9 5EQ, England,  
34 <https://orcid.org/0000-0001-9697-0340>  
35 Gavin Dabrera, FFPH, UKHSA COVID-19 National Epidemiology Cell, London, NW9 5EQ, England,  
36 <https://orcid.org/0000-0003-4606-5945>  
37 Simon Thelwall, PhD, UKHSA COVID-19 National Epidemiology Cell, London, NW9 5EQ, England,  
38 <https://orcid.org/0000-0002-0434-2724>

39 **Abstract**

40 Objectives

41 Sotrovimab is one of several therapeutic agents that have been licensed to treat people at risk of severe  
42 outcomes following COVID-19 infection. However, there are concerns that it has reduced efficacy to treat  
43 people with the BA.2 sub-lineage of the Omicron (B.1.1.529) SARS-CoV-2 variant. We compared individuals  
44 with the BA.1 or BA.2 sub-lineage of the Omicron variant treated Sotrovimab in the community to assess their  
45 risk of hospital admission.

46

47 Methods

48 We performed a retrospective cohort study of individuals treated with Sotrovimab in the community and either  
49 had BA.1 or BA.2 variant classification.

50

51 Results

52 Using a Stratified Cox regression model it was estimated that the hazard ratios (HR) of hospital admission with  
53 a length of stay of two or more days was 1.17 for BA.2 compared to BA.1 (95% CI 0.74-1.86) and for such  
54 admissions where COVID-19 ICD-10 codes was recorded the HR was 0.98 (95% CI 0.58-1.65).

55

56 Conclusion

57 These results suggest that the risk of hospital admission is similar between BA.1 and BA.2 cases treated with  
58 Sotrovimab in the community.

## 59 **Background**

60

61 The use of therapeutic agents for the treatment of COVID-19 is a rapidly evolving field of research where  
62 several new and existing treatments have been licensed to help treat COVID-19 infection in people who are at  
63 highest risk of developing severe outcomes. In the United Kingdom (UK), neutralising monoclonal antibody  
64 (nMAb) Sotrovimab was approved in December 2021 for use in symptomatic people who do not require oxygen  
65 but are at increased risk of severe infection. It was licenced to treat SARS-CoV-2 infection both for people in  
66 the community and those hospitalised (1).

67

68 Initial analyses of Sotrovimab have shown that its administration significantly reduced the risk of hospitalisation  
69 or death in people with mild to moderate infection who had at least one risk factor for developing severe  
70 outcomes (2, 3). However, findings from in vitro studies have raised concerns that Sotrovimab may have  
71 reduced clinical efficacy for people with the BA.2 sub-lineage of the Omicron (B.1.1.529) variant due to  
72 mutations in the spike protein causing reduced neutralising ability (4, 5). These concerns led to withdrawal of  
73 Sotrovimab authorisation in several countries including the United States of America (6). Sotrovimab is still  
74 licenced for use in the UK but it is currently the third-line recommended treatment for people in hospital (7) and  
75 as of June 2022 is more commonly given to people in the community (8). An initial analysis by the UK Health  
76 Security Agency (UKHSA) found that there was no increased risk of attendance or admission to hospital,  
77 however this was limited by reduced follow up time (9). Therefore, this study sought to assess whether there  
78 were any differences in hospital admission among people who were treated with Sotrovimab in community  
79 settings with BA.2 compared to those with BA.1 sub-lineages.

80

## 81 **Methods**

82

83 Information about individuals treated with Sotrovimab in the community submitted by NHS Trusts up to 24  
84 May 2022 were extracted from Blueteq software and linked deterministically by NHS number to laboratory  
85 confirmed COVID-19 cases in England from UKHSA's Second Generation Surveillance System (SGSS). This  
86 incorporates data on variant status from genotyping, S-gene target data and Whole Genome Sequencing (WGS)  
87 (10). Vaccination status of these cases was then obtained by linking to the National Immunisation Management  
88 Service (NIMS), and categorised based on receipt of vaccine at least two weeks prior to positive specimen date.

89 Cases were then linked to NHS Digital’s Emergency Care Data Set (ECDS) and Secondary Uses Service (SUS),  
90 for information about their hospital admissions as described elsewhere (11).

91

92 Genotyping can identify the Omicron variant but is unable to distinguish sub-lineages. However, the S-gene  
93 target status can be used in conjunction with genotyping PCR results to identify BA.1 and BA.2 for samples  
94 tested with the TaqPath assay, and therefore was used in conjunction with genotyping results, or used solely  
95 when Omicron was the dominant variant in circulation. The study therefore included: (1) all sequencing-  
96 confirmed BA.1 and BA.2 cases; (2) between 1 January and 24 January 2022 when Delta (B.1.617.2) variant  
97 was prevalent, SGTF/SGTP information was only used if genotyping PCR results indicated Omicron; and (3)  
98 from 25 January to 3 May 2022 all SGTF/SGTP cases were included irrespective of genotype status as  
99 predictive values of SGTF/SGTP to call BA.1/BA.2 were  $\geq 95\%$  (12).

100

101 Hazard ratios (HR) of hospitalisation outcomes for those treated with Sotrovimab with the BA.2 variant  
102 compared to BA.1 were estimated using Stratified Cox regression models. Hospital admission was defined as:  
103 (1) hospital admission with either a length of stay of two or more days, or the person died in hospital, (2)  
104 hospital admission with either a length of stay of two or more days, or the person died in hospital, and mention  
105 of COVID-19 ICD-10 codes (U071/U072). All definitions were restricted to be within 0-14 days from the date  
106 of treatment and excluded hospital admissions for injury-related reasons. Models were stratified by specimen  
107 week and then adjusted for age group, linear effect in age and vaccination status, to account for confounders. All  
108 analyses were performed in R (version 4.1.2, R Foundation for Statistical Computing, Vienna, Austria).

109 **Results**

110

111 Between 01 January and 26 April 2022 20,274 records for community prescription of Sotrovimab were  
112 received, 19,149 (94.5%) of which successfully linked to the COVID-19 case episodes list. 8,850 (46.2%) had  
113 BA.1 or BA.2 variant classification data available and were therefore included in analysis, 4,285 for BA.1 and  
114 4,565 for BA.2 respectively (Table 1).

115

116 The patient characteristics were broadly similar between the two cohorts, with the same proportions by sex. The  
117 BA.1 cohort had a younger age distribution compared to BA.2, where the median age of individuals with BA.1  
118 was 53 years (interquartile range 41-64) compared to 58 years for BA.2 (interquartile range 46-69). The  
119 geographical breakdown was broadly similar between the two groups, however slightly more of the BA.2 cohort  
120 resided in London compared to the BA.1 cohort ( $p<0.001$ ), while a slightly larger proportion of the BA.1 cohort  
121 resided in more-deprived areas compared to the BA.2 ( $p<0.001$ ).

122 **Table 1:** Demographic characteristics of COVID-19 cases treated with Sotrovimab in the community with  
 123 Omicron lineage BA.1 or BA.2: England, 1 January to 26 April 2022 (n = 8,850<sup>a</sup>)

Demographic		BA.1		BA.2	
		n	%	n	%
<b>Variant classification</b>	Validated sequencing	3,230	75.4%	3,566	78.1%
	Genotyping + S-Gene information	797	18.6%	698	15.3%
	S-Gene information only	258	6.0%	301	6.6%
<b>Sex</b>	Female	2,587	60.4%	2,725	59.7%
	Male	1,698	39.6%	1,840	40.3%
<b>Age</b>	10-19	77	1.8%	62	1.4%
	20-29	232	5.4%	190	4.2%
	30-39	602	14.0%	465	10.2%
	40-49	879	20.5%	735	16.1%
	50-59	981	22.9%	986	21.6%
	60-69	815	19.0%	1,013	22.2%
	70-79	556	13.0%	849	18.6%
	≥80	143	3.3%	265	5.8%
<b>Ethnic group</b>	Asian	247	5.8%	194	4.2%
	Black	101	2.4%	99	2.2%
	Mixed/Other	84	2.0%	85	1.9%
	Unknown	103	2.4%	96	2.1%
	White	3,750	87.5%	4,091	89.6%
<b>Region</b>	East Midlands	485	11.3%	441	9.7%
	East of England	752	17.5%	869	19.0%
	London	626	14.6%	787	17.2%
	North East	245	5.7%	261	5.7%
	North West	538	12.6%	489	10.7%
	South East	593	13.8%	661	14.5%
	South West	308	7.2%	357	7.8%
	West Midlands	456	10.6%	449	9.8%
	Yorkshire and Humber	282	6.6%	251	5.5%
<b>Indices of multiple deprivation (IMD) quintile</b>	1 (Most deprived)	590	13.8%	536	11.7%
	2	736	17.2%	778	17.0%
	3	909	21.2%	993	21.8%
	4	996	23.2%	1,057	23.2%
	5 (Least deprived)	1,054	24.6%	1,201	26.3%
<b>Vaccination status<sup>b</sup></b>	Unvaccinated or <28 days after first dose	62	1.4%	56	1.2%
	≥28 days after first dose	44	1.0%	32	0.7%
	≥14 days after second dose	4,136	96.5%	4,432	97.1%
	≥14 days after third dose	43	1.0%	45	1.0%
<b>Total</b>		4,285	100%	4,565	100%

124 <sup>a</sup> Cases in study period excluded from study and not shown in table: 1,125 Sotrovimab records failed to match  
 125 on NHS number to COVID-19 cases data, 14 missing data on key covariates, 212 with incomplete follow-up  
 126 time.

127 <sup>b</sup> Vaccination status was categorised based on receipt of vaccine at least two weeks prior to positive specimen  
 128 date

129 The risk of hospital admission with a length of stay of 2 or more days within 14 days of community treatment  
130 with Sotrovimab showed no statistically significant difference between BA.2 and BA.1 sub-lineages (HR=1.17,  
131 95% CI 0.74-1.86; Table 2). A sensitivity analysis restricting to hospital records which stated COVID-19 ICD-  
132 10 codes on admission for greater specificity also showed no statistically significant difference in hospitalisation  
133 risk in BA.2 cases compared to BA.1 (HR=0.98, 95% CI 0.58-1.65).

134

135 **Table 2:** Risk of hospitalisation for COVID-19 cases treated with Sotrovimab in the community with Omicron  
136 lineage BA.1 or BA.2: England, 1 January to 26 April 2022

Outcome	Count of outcome in BA.1 cases	Count of outcome in BA.2 cases	Adjusted hazard ratio (95% CI) <sup>a</sup>
Hospital admission with length of stay $\geq$ 2 days	91	77	1.17 (0.74 - 1.86)
Hospital admission with length of stay $\geq$ 2 days and mention of COVID-19 ICD-10 codes	73	62	0.98 (0.58 - 1.65)

137 <sup>a</sup> Adjusted hazard ratios and 95% confidence intervals (CI) from Cox regression models with an interaction term  
138 between variant (BA.2 vs BA.1). The models were stratified for specimen week, and additionally using  
139 regression adjustments for age group, linear effect in age and vaccination status, to account for confounders.

140

## 141 Discussion

142

143 These results suggest that there is no statistically significant difference in the risk of hospital admission between  
144 BA.1 and BA.2 cases treated with Sotrovimab in this English community cohort. This absence of difference  
145 persists when restricting to those admitted with a diagnosis of COVID-19.

146

147 These findings are supported by the access to high quality data on therapeutics prescribed to COVID-19 cases  
148 linked to national datasets, permitting a timely nationwide cohort study. Ascertaining case variant status through  
149 multiple methods allowed for a greater sample size than would otherwise be possible. Stratifying by specimen  
150 week and removing cases with insufficient follow-up time aimed to mitigate the reporting lags observed in  
151 routine hospitalisation surveillance data, but some bias may remain.

152

153 There are several limitations to this study, primarily NHS numbers were required to link the therapeutic data to  
154 the COVID-19 cases data, and subsequent vaccination and hospitalisation data which meant 1,125 community  
155 Sotrovimab records were excluded from the analysis. This analysis was also limited by overall number of cases  
156 available for inclusion, with variable testing guidance in England throughout the period and restrictions in free



157 community testing from 1 April 2022. Whilst therapeutic agent recipients and hospitalised cases are prioritised  
158 for both testing and sequencing (13), the period saw a significant reduction in sequencing capacity which may  
159 have limited the study size. Additional limitations include lack of information on co-morbidities of cases, and  
160 alternative measures of clinical severity such as people requiring ventilator support or admittance to intensive  
161 care units. Furthermore, the vaccination data available did not include the spring booster doses at the time of  
162 analysis.

163

164 It remains possible that Sotrovimab has lower clinical effectiveness for people with both BA.1 and BA.2,  
165 compared to previously circulating variants such as Delta (B.1.617.2), however due to the lack of cases of BA.2  
166 and Delta occurring in the same time period, it is not possible to compare severe outcomes following  
167 Sotrovimab treatment between these cases.

168

169 While this analysis shows that there is no apparent reduction in Sotrovimab effectiveness against BA.2  
170 compared to BA.1 in this cohort, it is important that Sotrovimab continues to be monitored so that treatment  
171 guidance can be updated when necessary. This is particularly important as new variants emerge, such as the  
172 BA.4 and BA.5 lineages of Omicron.

173

#### 174 **Acknowledgments**

175 The authors appreciate the contributions of Tommy Nyberg, Anne Presanis and Daniela De Angelis from MRC  
176 Biostatistics Unit, University of Cambridge for their expert advice.

177

#### 178 **Funding**

179 This work was performed as part of UKHSA's responsibility to monitor COVID-19.

180

#### 181 **Author contributions**

182 ST, KH, and GD conceived and designed the study. KH prepared the datasets and performed the statistical  
183 analysis, supported by HHW. KH and SGN drafted the first version of the manuscript. All authors read, revised  
184 and approved the final version of the manuscript.

185

186 **Potential conflicts of interest**

187 GD declares that his employer's predecessor organisation, Public Health England, received funding from  
188 GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no  
189 relation to COVID-19, and GD had no role in and received no funding from the project. All other authors report  
190 no potential conflicts.

191

192 **Ethics Approval**

193 UKHSA has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information)  
194 Regulations 2002 to process confidential patient information under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and  
195 3(iii) as part of its outbreak response activities. This study falls within the research activities approved by the  
196 UKHSA Research Ethics and Governance Group.

197

198 **Data availability**

199 The individual-level nature of the data used risks individuals being identified, or being able to self-identify, if  
200 the data are released publicly. Requests for access to these non-publicly available data should be directed to  
201 UKHSA.

202

203 **Consent to Participate**

204 Not applicable.

205

206 **Consent to Publish**

207 Not applicable.

## 208 References

- 209 1. Medicines and Healthcare products Regulatory Agency. Regulatory approval of Ronapreve 2021  
210 [Available from: <https://www.gov.uk/government/publications/regulatory-approval-of-ronapreve>.
- 211 2. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, et al. Effect of  
212 Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A  
213 Randomized Clinical Trial. *Jama*. 2022;327(13):1236-46.
- 214 3. Martin-Blondel G, Marcelin A-G, Soulié C, Kaiseridi S, Lusivika-Nzinga C, Dorival C, et al. Outcome  
215 of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort  
216 study (the ANRS 0003S COCOPREV study). *J Infect*. 2022:S0163-4453(22)00196-7.
- 217 4. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of Antiviral  
218 Agents against the SARS-CoV-2 Omicron Subvariant BA.2. *New England Journal of Medicine*.  
219 2022;386(15):1475-7.
- 220 5. Zhou H, Tada T, Dcosta BM, Landau NR. Neutralization of SARS-CoV-2 Omicron BA.2 by  
221 Therapeutic Monoclonal Antibodies. *bioRxiv*. 2022:2022.02.15.480166.
- 222 6. U.S. Food & Drug Administration. FDA updates Sotrovimab emergency use authorization 2022  
223 [Available from: [https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization)  
224 [use-authorization](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization).
- 225 7. Department of Health and Social Care, The Scottish Government, Welsh Government, Department of  
226 Health, NHS. Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the  
227 treatment of hospital-onset COVID-19 (Version 6) 2022 [Available from:  
228 [https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-antivirals-or-](https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-antivirals-or-neutralising-monoclonal-antibodies-in-the-treatment-of-hospital-onset-covid-19/)  
229 [neutralising-monoclonal-antibodies-in-the-treatment-of-hospital-onset-covid-19/](https://www.england.nhs.uk/coronavirus/publication/interim-clinical-commissioning-policy-antivirals-or-neutralising-monoclonal-antibodies-in-the-treatment-of-hospital-onset-covid-19/).
- 230 8. NHS England. COVID-19 Therapeutics (antivirals, neutralising monoclonal antibodies and interleukin  
231 6 inhibitors) 2022 [Available from: [https://www.england.nhs.uk/statistics/statistical-work-areas/covid-](https://www.england.nhs.uk/statistics/statistical-work-areas/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies/)  
232 [therapeutics-antivirals-and-neutralising-monoclonal-antibodies/](https://www.england.nhs.uk/statistics/statistical-work-areas/covid-therapeutics-antivirals-and-neutralising-monoclonal-antibodies/).
- 233 9. UK Health Security Agency. COVID-19 therapeutic agents: technical briefing 3 2022 [Available from:  
234 <https://www.gov.uk/government/publications/covid-19-therapeutic-agents-technical-briefings>.
- 235 10. Clare T, Twohig KA, O'Connell AM, Dabrera G. Timeliness and completeness of laboratory-based  
236 surveillance of COVID-19 cases in England. *Public Health*. 2021;194:163-6.
- 237 11. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission  
238 and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants  
239 of concern: a cohort study. *Lancet Infect Dis*. 2022;22(1):35-42.
- 240 12. UK Health Security Agency. UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern  
241 and variants under investigation in England. Technical briefing 36 London2022 [Available from:  
242 <https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings>.
- 243 13. Cabinet Office. COVID-19 Response: Living with COVID-19 2022 [Available from:  
244 <https://www.gov.uk/government/publications/covid-19-response-living-with-covid-19>.  
245